A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

October 15, 2028

Study Completion Date

October 15, 2030

Conditions
Follicular Lymphoma
Interventions
DRUG

Mosunetuzumab (IV)

Participants will receive IV mosunetuzumab as defined by the study protocol

DRUG

Tocilizumab

Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol

DRUG

Lenalidomide

Participants will receive oral lenalidomide as defined by the study protocol

DRUG

Mosunetuzumab (SC)

Participants will receive SC mosunetuzumab as defined by the study protocol

Trial Locations (32)

28040

ACTIVE_NOT_RECRUITING

Hospital Universitario Fundacion Jimenez Diaz., Madrid

29010

ACTIVE_NOT_RECRUITING

Hospital Universitario Virgen de la Victoria, Málaga

31059

WITHDRAWN

Institut Claudius Regaud, Toulouse

34295

WITHDRAWN

CHU Montpellier, Montpellier

35033

ACTIVE_NOT_RECRUITING

CHU Rennes - Hopital Pontchaillou, Rennes

37007

WITHDRAWN

Complejo Asistencial Universitario de Salamanca, Salamanca

37067

RECRUITING

Tennessee Oncology PLLC - Franklin, Franklin

37404

RECRUITING

Tennessee Oncology;Chattanooga Oncology & Hematology Associates, Chattanooga

44111

RECRUITING

Fairview Hospital, Cleveland

44124

RECRUITING

Hillcrest Hospital, Mayfield Heights

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

59037

WITHDRAWN

CHRU de Lille - Hopital Claude Huriez, Lille

69495

ACTIVE_NOT_RECRUITING

Centre Hospitalier Lyon Sud, Pierre-Bénite

70809

RECRUITING

Mary Bird Perkins Cancer Ctr, Baton Rouge

75475

WITHDRAWN

Hôpital Saint-Louis, Paris

91010

RECRUITING

City of Hope National Medical Center, Duarte

98122

RECRUITING

Swedish Medical Center, Seattle

130021

RECRUITING

the First Hospital of Jilin University, Changchun

200120

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

300060

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjing

361003

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

410013

WITHDRAWN

Hunan Cancer Hospital, Changsha

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

27710-4000

RECRUITING

Duke University Medical Center, Durham

44195-0001

RECRUITING

Cleveland Clinic, Cleveland

02895-4720

RECRUITING

Rhode Island Hematology/Oncology Program, Woonsocket

08035

WITHDRAWN

Hospital Universitario Vall d Hebron, Barcelona

NW1 2PG

ACTIVE_NOT_RECRUITING

University College London Hospitals NHS Foundation Trust - University College Hospital, London

M20 4BX

ACTIVE_NOT_RECRUITING

The Christie NHS Foundation Trust, Manchester

NE7 7DN

COMPLETED

Freeman Hospital, Newcastle upon Tyne

NG5 1PB

ACTIVE_NOT_RECRUITING

Nottingham University Hospitals NHS Trust - City Hospital, Nottingham

OX3 7LE

WITHDRAWN

Oxford University Hospitals NHS Foundation Trust, Oxford

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY